The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...

These peptides inhibited TLR signaling in macrophages, reducing inflammatory activity and demonstrating therapeutic potential in conditions such as sepsis and age-related macular degeneration (AMD).

Australia's Therapeutic Goods Administration has approved the use of a new and first treatment for geographic atrophy - a disease which causes severe ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...

Study from Case Western Reserve University and VA Northeast Ohio Healthcare System examines genetic risk profiles across ...

In the last 20 years, there have been rapid advances in the treatment options ... patients with myopic macular degeneration complicated by CNV may benefit from a new ophthalmic frontier of ...

In this Healio Video Perspective from Retina 2025, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses positive data for ...

Kyung Bo Kim discovered compounds that improved cognitive function regardless of amyloid plaque buildup — an encouraging sign ...

Sitala Bio Ltd. has prepared new indole derivatives acting as complement factor B (CFB) inhibitors. They are thus reported to be useful for the treatment of age-related macular degeneration, ...

Gemvax & Kael Co. Ltd. has identified peptides reported to be useful for the treatment of age-related macular degeneration (AMD), cerebral amyloid angiopathy and Alzheimer’s disease.

The company says that in pre-clinical tests performed on 30 people with macular degeneration, all of the participants experienced a reading speed increase of at least 50% when using the glasses.